Abstract
Introduction: Psychiatric disorders such as schizophrenia require appropriate treatment. Second-generation antipsychotics, including olanzapine, are administered as an appropriated treatment for these disorders. However, this drug has several complications, such as obesity and increased waist circumference which reduces the acceptance of the treatment. Objectives: The aim of this study was to investigate the effects of vitamin D3 therapy on waist circumference caused by olanzapine. Patients and Methods: In this randomized clinical trial, 50 hospitalized women with psychiatric disorders receiving olanzapine were divided into two groups of intervention and control groups. Before the intervention, the waist circumference, hip circumference, and waist-hip ratio were measured. Then, for 12 weeks, the intervention group received vitamin D3 and the control group received paraffin as the placebo, one pearl every 2 weeks. Waist circumference, hip circumference, and waist-hip ratio were re-measured and the collected data were analyzed by pair t test. Results: Our findings showed that there is a significant decrease in waist circumference and waist-hip ratio in intervention group (P<0.001). However, these changes were not significant in the placebo group. Hip circumference was not changed significantly in both groups. Conclusion: Vitamin D can be administered concomitant with 0lanzapine to improve side effects of olanzapine such as increasing waist circumference.
Highlights
Psychiatric disorders, including schizophrenia and mood disorders, require effective and appropriate treatment
The results showed that body mass index (BMI), waist circumference, waist-hip ratio, obesity and abdominal obesity was lower in the group without vitamin D deficiency, as compared to the group with vitamin D deficiency
Waist circumference in the intervention group had a statistically significant difference before and after the administration of vitamin D3 (P
Summary
Psychiatric disorders, including schizophrenia and mood disorders, require effective and appropriate treatment. Olanzapine is a second-generation antipsychotic drug that has very low-peripheral side effects and is administered to treat various psychiatric disorders including psychosis, obsessive-compulsive or bipolar disorders. This drug is administered for the treatment of Huntington’s disease. Olanzapine has several side effects, including weight gain, increasing blood lipids, and increasing risk of diabetes and cardiovascular disease. Central obesity and a high waist-hip ratio of over 0.9 in females and over one in males are independently associated with a higher risk of metabolic syndrome (1). Metabolic syndrome is defined as: 1) Abdominal obesity as waist circumference above 102 cm in males and above 88 cm in females.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
